文献速递核素与放射性配体治疗神经核医学

生长抑素受体靶向放射肽治疗难治性脑膜瘤:个体患者数据荟萃分析

Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis.
PubMed 文献 · J Nucl Med · 2020-08-28

该个体患者数据荟萃分析纳入6项队列研究共111例难治性脑膜瘤患者,评估SSTR靶向PRRT的毒性、疗效及生存。疾病控制率达63%,6个月PFS率在WHO I、II、III级分别为94%、48%、0%;1年OS率分别为88%、71%、52%。总给予活度每增加1,000 MBq,疾病进展风险降低13%,死亡风险降低17%。

要点

  • SSTR靶向PRRT在难治性脑膜瘤中疾病控制率达63%,总体耐受性良好。
  • WHO分级越高,6个月PFS率越低(I级94%、II级48%、III级0%)。
  • 总给予活度每增加1,000 MBq,进展风险降13%、死亡风险降17%。

核心结论

  • SSTR靶向PRRT治疗难治性脑膜瘤耐受性良好,多数患者获得疾病控制,PFS和OS结果令人鼓舞。

研究设计与样本

  • 个体患者数据荟萃分析,筛选537篇文献后纳入6项合格队列研究,共111例接受SSTR靶向PRRT的难治性脑膜瘤患者。
  • 采用Kaplan-Meier法估计生存概率,报告每100人年发病率,并用Cox比例风险模型分析协变量效应。

主要发现

  • 63%的患者达到疾病控制。
  • 6个月PFS率在WHO I、II、III级分别为94%、48%、0%。
  • 1年OS率在WHO I、II、III级分别为88%、71%、52%。
  • 总给予活度每增加1,000 MBq,疾病进展风险降低13%,死亡风险降低17%。
  • 主要副作用为一过性血液毒性:贫血22%、白细胞减少13%、淋巴细胞减少24%、血小板减少17%。

临床怎么用

  • 对于治疗难治性脑膜瘤,可考虑SSTR靶向PRRT,尤其WHO I–II级患者可能获益更明显。
  • 治疗中需监测一过性血液毒性,并根据WHO分级和给予活度评估获益与风险。

局限性

  • 纳入研究数量较少(6项队列研究),样本量有限(111例),证据级别受原始研究设计限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mirian C, Duun-Henriksen AK, Maier A, et al. Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. J Nucl Med. 2020. PMID: 32859705. doi:10.2967/jnumed.120.249607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。